Design, Synthesis, and Biological Investigation of Thailanstatin A and Spliceostatin D Analogues Containing Tetrahydropyran, Tetrahydrooxazine, and Fluorinated Structural Motifs

2021 ◽  
Vol 86 (3) ◽  
pp. 2499-2521
Author(s):  
K. C. Nicolaou ◽  
Santhosh Reddy Rekula ◽  
S. Mothish Kumar ◽  
Ananda Rao Podilapu ◽  
Ryan P. Matuszak ◽  
...  
2017 ◽  
Vol 27 (17) ◽  
pp. 3974-3979 ◽  
Author(s):  
Harbinder Singh ◽  
Jatinder V. Singh ◽  
Manish K. Gupta ◽  
Ajit K. Saxena ◽  
Sahil Sharma ◽  
...  

2009 ◽  
Vol 17 (11) ◽  
pp. 3829-3837 ◽  
Author(s):  
El-Shimaa M.N. Abdel-Hafez ◽  
Gamal El-Din A.A. Abuo-Rahma ◽  
Mohamed Abdel-Aziz ◽  
Mohamed F. Radwan ◽  
Hassan H. Farag

Molecules ◽  
2020 ◽  
Vol 25 (15) ◽  
pp. 3496 ◽  
Author(s):  
Irina V. Il’ina ◽  
Nadezhda S. Dyrkheeva ◽  
Alexandra L. Zakharenko ◽  
Alexander Yu. Sidorenko ◽  
Nikolay S. Li-Zhulanov ◽  
...  

Two novel structural types of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors with hexahydroisobenzofuran 11 and 3-oxabicyclo [3.3.1]nonane 12 scaffolds were discovered. These monoterpene-derived compounds were synthesized through preliminary isomerization of (+)-3-carene to (+)-2-carene followed by reaction with heteroaromatic aldehydes. All the compounds inhibit the TDP1 enzyme at micro- and submicromolar levels, with the most potent compound having an IC50 value of 0.65 μM. TDP1 is an important DNA repair enzyme and a promising target for the development of new chemosensitizing agents. A panel of isogenic clones of the HEK293FT cell line knockout for the TDP1 gene was created using the CRISPR-Cas9 system. Cytotoxic effects of topotecan (Tpc) and non-cytotoxic compounds of the new structures were investigated separately and jointly in the TDP1 gene knockout cells. For two TDP1 inhibitors, 11h and 12k, a synergistic effect was observed with Tpc in the HEK293FT cells but was not found in TDP1 −/− cells. Thus, it is likely that the synergistic effect is caused by inhibition of TDP1. Synergy was also found for 11h in other cancer cell lines. Thus, sensitizing cancer cells using a non-cytotoxic drug can enhance the efficacy of currently used pharmaceuticals and, concomitantly, reduce toxic side effects.


2020 ◽  
Vol 142 (36) ◽  
pp. 15476-15487
Author(s):  
K. C. Nicolaou ◽  
Johannes Krieger ◽  
Ganesh M. Murhade ◽  
Parthasarathi Subramanian ◽  
Balu D. Dherange ◽  
...  

ACS Omega ◽  
2020 ◽  
Vol 5 (17) ◽  
pp. 10089-10098 ◽  
Author(s):  
Ramar Sivaramakarthikeyan ◽  
Shunmugam Iniyaval ◽  
Vadivel Saravanan ◽  
Wei-Meng Lim ◽  
Chun-Wai Mai ◽  
...  

Molecules ◽  
2020 ◽  
Vol 25 (18) ◽  
pp. 4107
Author(s):  
Lanchang Gao ◽  
Zhengge Yang ◽  
Jiaying Xiong ◽  
Chao Hao ◽  
Ru Ma ◽  
...  

The design of a series of novel flavone derivatives was synthesized as potential broad-spectrum antipsychotics by using multi-receptor affinity strategy between dopamine receptors and serotonin receptors. Among them, 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin- 1-yl) butoxy)-2,2-dimethylchroman-4-one (6j) exhibited a promising preclinical profile. Compound 6j not only showed high affinity for dopamine D2, D3, and serotonin 5-HT1A, 5-HT2A receptors, but was also endowed with low to moderate activities on 5-HT2C, α1, and H1 receptors, indicating a low liability to induce side effects such as weight gain, orthostatic hypotension and QT prolongation. In vivo behavioral studies suggested that 6j has favorable effects in alleviating the schizophrenia-like symptoms without causing catalepsy. Taken together, compound 6j has the potential to be further developed as a novel atypical antipsychotic.


Sign in / Sign up

Export Citation Format

Share Document